{"doi":"10.4088/jcp.22br14567","title":"Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder","abstract":"T he high incentive value attributed to a drug in substance use disorders leads to the heightened dopaminergic responses to drug-related conditioned stimuli (ie, cue reactivity), 1 stimulating drug-seeking behavior and promoting relapse. Specifically, in opioid use disorder (OUD), greater NAcc response to opioid drug cues has been associated with heavier drug use. The once-monthly injectable extended-release opioid antagonist naltrexone (XR-NTX) is an effective relapse prevention medication for OUD 4,5 that significantly reduces NAcc cue reactivity. Depression and OUD are highly comorbid, 8,9 and both involve endogenous opioid dysregulation. atients with more severe depressive symptoms show poorer response to OUD treatment. 12-14 Here, we used functional magnetic resonance imaging (fMRI) to test the hypothesis that depressive symptomatology in OUD is associated with reduced sensitivity of subjective or neural indices of drug cue reactivity to the XR-NTX treatment of OUD.","journal":"The Journal of Clinical Psychiatry","year":2023,"id":378529,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9426,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1052797,"name":"Xinyi Li","orcid":"0000-0003-3136-4811","position":1,"is_corresponding":false},{"id":397020,"name":"Kyle M. Kampman","orcid":"0000-0002-9760-8324","position":2,"is_corresponding":false},{"id":454161,"name":"Anna Rose Childress","orcid":null,"position":3,"is_corresponding":false},{"id":301109,"name":"Corinde E. Wiers","orcid":"0000-0002-2934-8794","position":4,"is_corresponding":false},{"id":346407,"name":"Daniel D. Langleben","orcid":null,"position":5,"is_corresponding":false},{"id":927448,"name":"Zhenhao Shi","orcid":"0000-0001-5697-2034","position":0,"is_corresponding":true}],"reference_count":36,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T01:16:48.594070Z","pmid":"37074295","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}